RESPIRATORY
PATHOGEN
PANEL (RPP)
Respiratory infections are caused by bacteria and viruses in both the upper and lower respiratory tracts of patients. These infections commonly result in symptoms such as:
THESE INFECTIONS PRODUCE MANY COMMON CLINICAL SYMPTOMS SUCH AS:
- Rhinitis
- Sinusitis
- Pertussis
- Laryngitis
- Pharyngitis
- Influenza
- Infectious Mononucleosis
Upper Respiratory Tract Infections (URTI)
- Rhinitis
- Sinusitis
- Pertussis
- Laryngitis
- Pharyngitis
- Influenza
- Infectious Mononucleosis
Lower Respiratory Tract Infections (LRTI)
- Pneumonia
- Bronchitis
- Bronchiolitis
- Pleuritis
- Empyema
Acute respiratory infections pose significant risks for morbidity and mortality in young, geriatric, and immunocompromised patients. These populations are particularly prone to co-infections, underscoring the need for advanced diagnostic technologies capable of detecting multiple pathogens simultaneously. Timely and accurate detection is crucial to avoid false negative results, which can lead to delayed diagnoses and adverse clinical outcomes.
At Augustus Laboratories, our Respiratory Pathogen Panel (RPP) employs advanced molecular diagnostic techniques, including Polymerase Chain Reaction (PCR) and Reverse Transcription Polymerase Chain Reaction (RT-PCR). These technologies swiftly and precisely identify a broad spectrum of respiratory pathogens, while also detecting antibiotic resistance markers within the pathogens.
- Provides a more definitive diagnosis than point-of-care antigen assays
- 24-hour turnaround from specimen receipt
- More accurate, without the wait times of conventional culture
- CAP accredited/CLIA certified laboratory
THESE INFECTIONS PRODUCE MANY COMMON CLINICAL SYMPTOMS SUCH AS:
- • Detects polymicrobial infections
- • Unaffected by concurrent antibiotic use
- • Identifies potential antibiotic resistance
- • Aids in quick clinical decision-making
- • Reduces false negative results
- • Aids in antibiotic stewardship
- • Reduces potential unnecessary drug exposure and adverse events
Upper Respiratory Tract Infections (URTI)
- Adenovirus Bordetella pertussis
- Coronavirus HKU
- Coronavirus OC43
- Haemophilus influenzae
- Influenza A
- Legionella pneumophila
- Moraxella catarrhalis
- Mycobacterium kansasii
- Mycoplasma pneumoniae
- Parainfluenza Virus 4
- Rhinovirus 1
- Staphylococcus aureus
- Coronavirus 229E
- Coronavirus NL63
- Streptococcus pyogenes (Group A)
- Human Bocavirus (HBoV)
- Influenza B
- Metapneumovirus
- Mycobacterium tuberculosis complex
- Mycobacterium intracellulare
- Parainfluenza Virus 1/2/3
- Respiratory Syncytial Virus A
- Pseudomonas aeruginosa
- Streptococcus pneumoniae
Lower Respiratory Tract Infections (LRTI)
- Bordetella pertussis
- Coronavirus 229E
- Coronavirus NL63
- Haemophilus influenzae
- Influenza B
- Metapneumovirus
- Mycobacterium tuberculosis complex
- Mycobacterium intracellulare
- Rhinovirus 1
- Chlamydophila pneumoniae
- Coronavirus HKU1
- Coronavirus OC43
- Influenza A
- Legionella pneumophila
- Moraxella catarrhalis
- Mycobacterium kansasii
- Respiratory Syncytial Virus A
- Streptococcus pneumoniae
ANTIBIOTIC RESISTANCE
- Tetracycline Resistance
- Class A and D Beta-lactamase
- ERM Macrolide Resistance
- AmpC and ESBL
- MefA Macrolide Resistance
- Methicillin Resistance
- CTX-M Class A Betalactamase
- Vancomycin Resistance
- AmpC Betalactamase
- Dihydrofolate and Sulfonamide Resistance
- Carbapenemase and Matallo-Betalactamase
- Resistance
- KPC Carbapenemase
- Cfr Macrolide
- OXA-48 Class D Betalactamase
- Quinolone Resistance
Augustus Laboratories’ Molecular Respiratory Pathogen Test (RPP) rapidly identifies respiratory pathogens and detects antibiotic resistance markers, facilitating prompt initiation of targeted therapeutic interventions.
